HKSE · 2563.HK
Beijing Biostar Pharms Co Ltd
HK$3.40-HK$0.15 (-4.23%)
Beijing Biostar Pharms Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 35.24% below the high.
Loading market information…
HKSE · 1228.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 06:45 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
CANbridge Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.43% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
CANbridge Pharmaceuticals Inc.’s next earnings report is currently expected on Apr 1, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow CANbridge Pharmaceuticals Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the global research, development, and commercialization of treatments for rare disorders and various cancer types. The company's marketed products include Hunterase, an enzyme replacement therapy for Hunter syndrome; NERLYNX (Neratinlib), a powerful, irreversible tyrosine kinase inhibitor targeting HER2-positive breast cancer; and Caphosol Mouth Rinse, used to alleviate temporary and persistent dry mouth and throat. Its robust development pipeline features several investigational therapies: CAN008, an artificially engineered antibody-like fully human fusion protein being developed for glioblastoma multiforme; CAN108, an orally administered reversible inhibitor of the ileal bile acid transporter, designed to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 for complement-mediated conditions; CAN103 and CAN104, both recombinant human enzyme replacement therapies (ERTs); CAN105, a bispecific antibody; and gene therapy programs CAN201 and CAN202, both utilizing adeno-associated virus (AAV) sL65 capsid technology. Established in 2012, CANbridge Pharmaceuticals Inc. is based in Beijing, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:07 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| HK$40.68M |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$3.40-HK$0.15 (-4.23%)
Beijing Biostar Pharms Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 35.24% below the high.
HK$11.21+HK$0.21 (+1.91%)
Wenzhou Kangning Hospital Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 4.19% below the high.
HK$1.36-HK$0.09 (-5.9%)
Kintor Pharmaceutical Limited’s quoted price sits in the lower half of its reported 52-week range, 71.17% below the high.
HK$3.39-HK$0.02 (-0.44%)
Hospital Corporation of China Limited’s quoted price sits in the lower half of its reported 52-week range, 50.8% below the high.
HK$4.13HK$0.00 (0.0%)
Sirnaomics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 61.47% below the high.
HK$0.47-HK$0.02 (-4.08%)
China Biotech Services Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 54.81% below the high.
HK$0.07+HK$0.00 (+3.08%)
Uni-Bio Science Group Limited’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
HK$1.39+HK$0.01 (+0.72%)
Suzhou Basecare Medical Corporation Limited’s quoted price sits in the lower half of its reported 52-week range, 47.55% below the high.
